BioDelivery Sciences International Stock Forecast, Price & News

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BDSI shares have increased by 2.8% and is now trading at $4.07.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioDelivery Sciences International.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Wednesday, August, 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.03. The specialty pharmaceutical company had revenue of $36.58 million for the quarter, compared to analyst estimates of $36.27 million. BioDelivery Sciences International had a return on equity of 17.84% and a net margin of 4.23%.
View BioDelivery Sciences International's earnings history.

8 brokers have issued 12-month target prices for BioDelivery Sciences International's stock. Their forecasts range from $7.00 to $9.25. On average, they anticipate BioDelivery Sciences International's share price to reach $8.46 in the next year. This suggests a possible upside of 108.0% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International.

BioDelivery Sciences International saw a drop in short interest in August. As of August 31st, there was short interest totaling 3,120,000 shares, a drop of 23.0% from the August 15th total of 4,050,000 shares. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is currently 2.7 days.
View BioDelivery Sciences International's Short Interest.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), NVIDIA (NVDA), Eldorado Gold (EGO), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.Com (JD), Baidu (BIDU), Square (SQ), Alibaba Group (BABA) and ACADIA Pharmaceuticals (ACAD).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (6.48%), Vanguard Group Inc. (4.65%), Emerald Advisers LLC (2.10%), Emerald Mutual Fund Advisers Trust (1.97%), Nuveen Asset Management LLC (1.80%) and Wasatch Advisors Inc. (1.44%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha, Thomas B Smith and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including Aigen Investment Management LP, ClariVest Asset Management LLC, Navellier & Associates Inc, AQR Capital Management LLC, UBS Group AG, Prudential Financial Inc., Silvercrest Asset Management Group LLC, and Searle & CO.. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, Thomas B Smith, and W Mark Watson.
View insider buying and selling activity for BioDelivery Sciences International.

BDSI stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Marshall Wace LLP, Assenagon Asset Management S.A., Deerfield Management Company L.P. Series C, Russell Investments Group Ltd., Wasatch Advisors Inc., Globeflex Capital L P, and MCF Advisors LLC.
View insider buying and selling activity for BioDelivery Sciences International.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BDSI stock can currently be purchased for approximately $4.07.

BioDelivery Sciences International has a market capitalization of $410.80 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

The official website for BioDelivery Sciences International is www.bdsi.com.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]